Debug Stats | ### Total Build Time: 21 ms 35.923 KB CONCEPT_NAME gt=1 ms Completed: 1 ms rowSize= 344 bytesCONCEPT_SOLR_HIT_STATS gt=0 Completed: 0 ms rowSize= 14 bytesCONCEPT_DEFINITION gt=0 Completed: 0 ms rowSize= 353 bytes- Skipping details on:
CONCEPT_SYNONYM gt=NONE 0 Completed: 0 ms rowSize= 0 bytes - Skipping details on:
CONCEPT_TEXT gt=NONE 0 Completed: 0 ms rowSize= 0 bytes CONCEPT_SEMANTIC_TYPE gt=0 Completed: 0 ms rowSize= 14 bytes- Skipping details on:
CONCEPT_NAMESPACE gt=NONE 0 Completed: 0 ms rowSize= 0 bytes CONCEPT_PARENTS gt=0 Completed: 0 ms rowSize= 7 bytesCONCEPT_CHILDREN gt=0 Completed: 0 ms rowSize= 8 bytesCONCEPT_ANCESTRAL_ROOTS gt=0 Completed: 0 ms rowSize= 15 bytesCONCEPT_RELATIONSHIPS gt=8 ms Completed: 8 ms rowSize= 13.787 KBCONCEPT_GENES gt=11 ms Completed: 11 ms rowSize= 20.228 KBCONCEPT_XREFS gt=0 Completed: 0 ms rowSize= 1.157 KBCONCEPT_ANCILLARY gt=1 ms Completed: 1 ms rowSize= 14 bytes- Reload Stats
|
Genes (17)
Species: human : 17 | |
Human | GGT2 | 728441 | gamma-glutamyltransferase 2 | The mean GGT activity in benign ovarian tumors was lower than that in malignant tumors. | Human | MSLN | 10232 | mesothelin | METHODS: We have evaluated a composite marker (CM) that combines CA 125 and a previously described soluble mesothelin related (SMR) marker in sera from 52 ovarian cancer cases, 43 controls with benign ovarian tumors, and 220 normal risk controls who participated in a screening program, including 25 healthy women having two serum samples collected 1 year apart. | Human | MVP | 9961 | major vault protein | The co-expression of MDR1, MRP, LRP and GST-pi is higher in ovarian cancer than that in benign ovarian tumor and normal ovary tissue. METHODS: The expression of MDR1, MRP, LRP and GST-pi in 41 cases of ovarian cancer, 25 cases of benign ovarian tumor and 12 normal ovary tissue were investigated by reverse transcription-polymerase chain reaction (RT-PCR). | Human | TK1 | 7083 | thymidine kinase 1, soluble | We examined TK1 gene expression by RT-PCR and related it to gene expression of TS, TP and DPD in 69 samples from epithelial ovarian cancer, 8 low-malignant-potential tumors, 16 benign ovarian tumors and 34 normal ovaries. | Human | SLC2A3 | 6515 | solute carrier family 2 (facilitated glucose transporter), member 3 | Only GLUT3 revealed weak but homogeneous expression in human ovarian cancer as well as in benign ovarian tumors. | Human | SEN6 | 6411 | senescence (cellular)-related 6 | Interestingly, the latter region was reported previously to be deleted in benign ovarian tumors and recently found to harbor a gene (SEN6) that is important for SV40-mediated immortalization of human cells. | Human | NME1 | 4830 | NME/NM23 nucleoside diphosphate kinase 1 | The expression of nm23, a putative metastasis-suppressor gene product, was assessed immunohistochemically in malignant and benign ovarian neoplasms, considering histology of tumors and clinical advancement of disease. | Human | LGALS3BP | 3959 | lectin, galactoside-binding, soluble, 3 binding protein | Elevated serum CA 125 and 90K levels were present in 32% and 29% of patients with benign ovarian tumors, respectively. | Human | LDHA | 3939 | lactate dehydrogenase A | From analysis of serum LDH isoenzymes, a significant decrease in LDH-1, and significant increases in LDH-4 and LDH-5 in ovarian cancer patients were observed, when compared with those in patients with benign ovarian tumor. | Human | STMN1 | 3925 | stathmin 1 | Quantitative Northern blot analysis of 12 malignant ovarian samples, 8 benign ovarian tumors, and 10 normal ovarian tissue samples demonstrated overexpression of Op18/stathmin mRNA in the malignant cancers. | Human | IL6ST | 3572 | interleukin 6 signal transducer (gp130, oncostatin M receptor) | Coexpression of IL-11Ralpha and gp130 was commonly observed in both benign ovarian tumors and in the epithelial layer of normal ovaries. | Human | IGFBP3 | 3486 | insulin-like growth factor binding protein 3 | To assess possible mutual correlations between alterations in circulating IGFBP profiles and tumuor markers in patients with epithelial ovarian cancer, we performed an RIA for IGFBP-2 and IGFBP-3 and a Western ligand blotting (WLB) in serum samples from 20 patients with epithelial ovarian cancer, 10 patients with benign ovarian tumors, and 8 healthy age-matched controls. | Human | IGFBP2 | 3485 | insulin-like growth factor binding protein 2, 36kDa | To assess possible mutual correlations between alterations in circulating IGFBP profiles and tumuor markers in patients with epithelial ovarian cancer, we performed an RIA for IGFBP-2 and IGFBP-3 and a Western ligand blotting (WLB) in serum samples from 20 patients with epithelial ovarian cancer, 10 patients with benign ovarian tumors, and 8 healthy age-matched controls. | Human | FH | 2271 | fumarate hydratase | two patients diagnosed with ovarian mucinous cystadenoma (two out of 33, 6%) were found to be FH germline mutation carriers; results suggest that benign ovarian tumors may be associated with hereditary leiomyomatosis and renal cell cancer (HLRCC) | Human | FGF4 | 2249 | fibroblast growth factor 4 | Amplification of hst1 was found in 1 benign ovarian tumor. | Human | CD68 | 968 | CD68 molecule | Paraffin-embedded tissues obtained from 52 ovarian carcinomas and 21 benign ovarian neoplasms were examined immunohistochemically to demonstrate suppressor/cytotoxic T cells and macrophages by using CD8 and CD68 monoclonal antibodies, respectively. | Human | CCNE1 | 898 | cyclin E1 | Primary, metastatic, recurrent and benign ovarian tumors were screened for cyclin E and cdk2 gene amplification. |
|